Correlation of the therapeutic effect of activated tumor-draining lymph node cells with specific interferon-γ production in vitro

Surgery Today

Volumn 29, Issue 1, 1999, Pages 55-62

  Sameshima, Shinichi ^a   Sakai, Keisuke ^b   Nagawa, Hirokazu ^a   Tsuno, Nelson ^a   Kitayama, Joji ^a   Muto, Tetsuichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Adoptive immunotherapy; Anti CD3 antibody; Interferon ; Interleukin 2; Tumor draining lymph node

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; LYMPH NODE CELL; MOUSE; NONHUMAN; PHENOTYPE; T LYMPHOCYTE; TUMOR;

EID: 0032931329     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02482971     Document Type: Article

References (32)

1. 1. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45:3735-3741
2. 2. Rosenberg SA (1988) The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 208:121-135
3. 3. Chou T, Chang AE, Shu SY (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 140:2453-2461
4. 4. Shu SY, Chou T, Rosenberg SA (1987) Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 139:295-304
5. 5. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
6. 6. Spiess PJ, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79:1067-1075
7. 7. Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD (1992) Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548-553
8. 8. Sakai K, Chang AE, Shu SY (1990) Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma. Cancer Res 50:4371-4376
9. 9. Cheever MA, Greenberg PD, Fefer A, Gillis S (1982) Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 155:968-980
10. 10. Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147:729-737
11. 11. Yoshizawa H, Sakai K, Chang AE, Shu SY (1991) Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 134:473-479
12. 12. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA (1991) T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 146:4414-4420
13. 13. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD (1993) Gamma-interferon plays a key role in T-cell-induced tumor regression. Cancer Res 53:833-839
14. 14. Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA (1991) Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173:647-658
15. 15. Maraskovsky E, Chen WF, Shortman K (1989) IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 143:1210-1214
16. 16. Donohue JH, Rosenstein M, Chang AE, Lotze MT, Robb RJ, Rosenberg SA (1984) The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. J Immunol 132:2123-2128
17. 17. Whittington R, Faulds D (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446-514
18. 18. Takeuchi M, Kimoto M, Suzuki I, Nomoto K (1983) Effect of BCG (bacillus Calmette Guerin) sensitization on the generation of tumor specific killer T cells (in Japanese). Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 10:1980-1986
19. 19. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA (1987) Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374-1378
20. 20. Devos R, Plaetinck G, Cheroutre H, Simons G, Degrave W, Tavernier J, Remaut E, Fiers W (1983) Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res 11:4307-4323
21. 21. Wexler H (1966) Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36:641-645
22. 22. Tyring S, Klimpel GR, Fleischmann WJ, Baron S (1982) Direct cytolysis by partially-purified preparations of immune Interferon. Int J Cancer 30:59-64
23. 23. Fox BA, Spiess PJ, Kasid A, Puri R, Mule JJ, Weber JS, Rosenberg SA (1990) In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes. J Biol Response Modifiers 9:499-511
24. 4. Flyer DC, Burakoff SJ, Faller DV (1985) Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. J Immunol 135:2287-2292
25. 25. Zoller M, Strubel A, Hammerling G, Andrighetto G, Raz A, Ben ZA (1988) Interferon-gamma treatment of B16 melanoma cells: opposing effects for non-adaptive and adaptive immune defense and its reflection by metastatic spread. Int J Cancer 41:256-266
26. 26. Weber JS, Rosenberg SA (1988) Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res 48:5818-5824
27. 27. Issekutz TB (1990) Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat. J Immunol 144:2140-2146
28. 28. Pace JL, Russell SW, Torres BA, Jonson HM, Gray PW (1983) Recombinant mouse gamma Interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130:2011-2013
29. 29. Gemlo BT, Palladino MJ, Jaffe HS, Espevik TP, Rayner AA (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 48:5864-5867
30. 30. Giannella G, Pelosi TE, Carlini P, Habetswallner D, Montesoro E, Camagna A, Calzini V, Ruggeri EM, Arena MG, Masciulli R, Bulgarini D, Samoggia P, Di Folco S, Petrillo G, Sofra MG, Boccoli G, Mastroberardino G, Calabrest F, Testa U, Peschle C (1989) Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells. Immunobiology 178:305-315
31. 31. Nishihara K, Miyatake S, Sakata T, Yamashita J, Kikuchi H, Kawade Y, Zu Y, Namba Y, Hanaoka M, Watanabe Y (1988) Augmentation of tumor targeting in a line of glioma-specific mouse cytotoxic T-lymphocytes by retroviral expression of mouse gamma-interferon complementary DNA. Cancer Res 48:4730-4735
32. 32. Miyatake S, Nishihara K, Kikuchi H, Yamashita J, Namba Y, Hanaoka M, Watanabe Y (1990) Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene. J Natl Cancer Inst 82:217-220